Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 2/20 | 0.41 |
| ▸ | THRA | P10827 | 10/20 | 0.39 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 9/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9417834 | 0.99 | LTB4R (0.39) | LTB4RTHRAPLA2G2DTHRBNR1H4 | |
| SCHEMBL9417814 | 0.93 | THRA (0.37) | LTB4RTHRAPLA2G2DTHRBNR1H4 | |
| SCHEMBL9417891 | 0.86 | MAPK1 (0.40) | THRB | |
| SCHEMBL10522356 | 0.82 | LTB4R (0.56) | LTB4RTHRAPLA2G2DTHRB | |
| SCHEMBL9387348 | 0.80 | LTB4R (0.48) | LTB4RTHRAPLA2G2DTHRB | |
| SCHEMBL6935194 | 0.79 | LTB4R (0.46) | LTB4RTHRAPLA2G2DTHRBPPARG | |
| SCHEMBL2422646 | 0.78 | LTB4R (0.45) | LTB4RTHRAPLA2G2DTHRBPPARG | |
| SCHEMBL5711634 | 0.78 | LTB4R (0.53) | LTB4RTHRAPLA2G2DTHRB | |
| Hydrochloric Acid SCHEMBL9417918 | 0.77 | LTB4R (0.45) | LTB4RTHRAPLA2G2DTHRBPPARG | |
| SCHEMBL9696996 | 0.77 | LTB4R (0.67) | LTB4RTHRAPLA2G2DPPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210695-A1 | COMPOSITIONS AND METHODS FOR TREATING SKIN DISORDERS | DARA BIOSCIENCES, INC. (US) | 2010-08-19 | — | — | US | disclosed |
| EP-1180686-B1 | REMEDIES FOR KIDNEY DISEASES AND METHOD FOR SCREENING THE SAME | CMIC CO LTD (JP) | 2009-10-14 | — | — | EP | disclosed |
| WO-2009002433-A1 | COMPOSITIONS AND METHODS FOR TREATING SKIN DISORDERS | DARA BIOSCIENCES, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| US-20060120971-A1 | Agents and methods for administration to the central nervous system | SIGNUM PHARMACEUTICALS, INC. | 2006-06-08 | — | — | US | disclosed |
| WO-2006041922-A2 | AGENTS AND METHODS FOR ADMINISTRATION TO THE CENTRAL NERVOUS SYSTEM | DARA BIOSCIENCES, INC. (US) | 2006-04-20 | — | — | WO | disclosed |
| WO-2005095649-A1 | DNA CHIP FOR SCREENING OF PEROXISOME PROLIFERATOR | GENOCHECK CO. LTD. (KR) | 2005-10-13 | — | — | WO | disclosed |
| US-20040185503-A1 | Administering peroxisome proliferator-activated receptor agonist; assaying substance for up-regulating the expression of fatty acid-binding protein; glomerulonephritis, nephrotic syndrome, focal glomerulosclerosis | TANABE SEIYAKU CO., LTD. | 2004-09-23 | — | — | US | disclosed |
| US-6794154-B1 | COMPRISES ASSAYING A TEST SUBSTANCE FOR THE ACTIVITY OF UP-REGULATING THE EXPRESSION OF LIVER-TYPE FATTY ACID-BINDING PROTEIN (L-FABP) IN ANIMAL CELLS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR AGONISTS; | TANABE SEIYAKU CO., LTD. (JP) | 2004-09-21 | — | — | US | disclosed |
| EP-1180686-A1 | REMEDIES FOR KIDNEY DISEASES AND METHOD FOR SCREENING THE SAME | TANABE SEIYAKU CO., LTD. (JP) | 2002-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210695-A1 | COMPOSITIONS AND METHODS FOR TREATING SKIN DISORDERS | CPT1B, CPT1A, CPT2 | LTB4R 1678/4885THRA 4193/4885PLA2G2D 1604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.